Symptoms & Symptom Management
Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Cancer Cytopathology 2023 April 17 [Link] Yili Zhu, Simone Moore, Aihui Wang, Elizabeth George, Grace M Allard, Diane M Libert, Alarice C Lowe Abstract Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case…
Read MoreEstablishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method
Biomedicine and Pharmacotherapy 2023 June [Link] Yomogi Sato, Mohamed Elbadawy, Kazuhiko Suzuki, Ryouichi Tsunedomi, Hiroaki Nagano, Yusuke Ishihara, Haru Yamamoto, Daigo Azakami, Tsuyoshi Uchide, Rina Nabeta, Ryuji Fukushima, Amira Abugomaa, Masahiro Kaneda, Hideyuki Yamawaki 10, Yuta Shinohara, Tatsuya Usui, Kazuaki Sasaki Abstract Canine malignant mesothelioma (cMM) is a rare and drug-resistant malignant tumor. Due to…
Read MoreThe cytological features of effusions with mesothelioma in situ: A report of 9 cases
Diagnostic Cytopathology 2023 March 21 [Link] Claire W Michael, Carlos C W M Bedrossian, Navid Sadri, Sonja Klebe Abstract Introduction: The diagnosis of mesothelioma in situ (MIS) is now accepted by the WHO as a pre-invasive neoplastic mesothelial proliferation and considered a diagnosis based on histologic evaluation only. Although the definition of MIS includes recurrent…
Read MoreA rare case of primary gastric Burkitt’s lymphoma associated with malignant pleural mesothelioma
Annali Italiani di Chirurgia 2023 March 6 [Link] Erasmo Spaziani, Annalisa Romina Di Filippo, Giampaolo Valle, Martina Spaziani, Piero Francioni, Gianluca Caruso, Giovanni Traumueller Tamagnini, Edoardo Mosciatti, Marcello Picchio, Alessandro De Cesare Abstract Background: Primary gastric Burkitt lymphoma (PG BL) and malignant pleural mesothelioma (MPM) are rare and aggressive tumors with poor prognosis. HIV and…
Read MoreA Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma
Heart, Lung, & Circulation 2023 March 14 [Link] Maryum Qureshi, Bibhusal Thapa, Sanjeevan Muruganandan Abstract Malignant pleural mesothelioma (MPM) is an aggressive, almost universally fatal cancer with limited therapeutic options. Despite efforts, a real breakthrough in treatment and outcomes has been elusive. Pleural effusion with significant breathlessness and pain is the most typical presentation of…
Read MoreTROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…
Read MoreMesothelioma In Situ Mimicking Well-differentiated Papillary Mesothelial Tumor
The American Journal of Surgical Pathology 2023 March 6 [Link] Francoise Galateau-Salle, Trevor Hamilton, Andrea MacNeill, Véronique Hofman, Ruth Sequeiros, Christine Sagan, Nolwenn Le Stang, Andrew Churg Abstract We have previously hypothesized that well-differentiated papillary mesothelial tumor (WDPMT) consists of 2 morphologically identical lesions, one of which is true WDPMT, while the other is a…
Read MoreNovel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
Lung Cancer 2023 April [Link] Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M Haikala, Olli Kallioniemi, Mikko I Mäyränpää, Ilkka Ilonen Abstract Objectives: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination…
Read MoreDefining and targeting tumor-associated macrophages in malignant mesothelioma
Proceedings of the National Academy of Sciences of the United States of America 2023 February 28 [Link] Licun Wu, Mikihiro Kohno, Junichi Murakami, Amin Zia, Jonathan Allen, Hana Yun, Meilin Chan, Cristina Baciu, Mingyao Liu, Veronique Serre-Beinier, Michele De Palma, Emanuela Felley-Bosco, Jonathan Yeung, Trevor J Pugh, Marc de Perrot Abstract Defining the ontogeny of…
Read MoreThe cytologic diagnosis of mesothelioma: are we there yet?
Journal of the American Society of Cytopathology 2022 December 26 [Link] Claire W Michael Abstract Introduction: Mesothelioma is a rare but highly aggressive malignancy with poor prognosis that frequently present with recurrent effusions. Establishing the diagnosis by cytology can lead to early diagnosis and treatment and consequently improve prognosis. Materials and methods: This review examines…
Read More